This is an excerpt from the original initial Phase IIb AIPAC results way back in March 25, 2020.
"AIPAC Principal Investigator, Hans Wildiers of University Hospitals Leuven, Leuven, Belgium, said: “I am
pleased to see this innovative chemo-immunotherapy approach in AIPAC is well tolerated by patients, while
showing a numerically (non-significant) higher progression free survival rate compared to chemotherapy
alone."
Which I guess speaks to the statistical significance of these results...
This is an excerpt from the original initial Phase IIb AIPAC...
-
- There are more pages in this discussion • 29 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.8¢ |
Change
0.003(0.85%) |
Mkt cap ! $421.2M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 30.0¢ | 28.5¢ | $789.2K | 2.720M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 14 | 245871 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 191147 | 26 |
View Market Depth
| Last trade - 11.59am 06/08/2024 (20 minute delay) ? |
| IMM (ASX) Chart |